A practical reference on Visceral adiposity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
== Science, technology and mathematics == Central limit theorem, in probability and statistics Construal level theory, a statistical social theory Central location test, a marketing research technique Cross-laminated timber, an engineered wood
Madak was a blend of opium and tobacco used as a recreational drug in 16th- and 17th-century China. It emerged in southern coastal areas in the first half of the 17th century. In the last quarter of the 18th century madak was phased out by raw opium. The prohibition of madak in 1729 may have been a contributing factor to the increase in popularity of smoking pure opium. Raw opium was introduced in China by Arab merchants. Rather than taking bitter raw opium orally, the Chinese attempted smoking opium mixed with other substances. According to Dikotter et al., smoking opium blended with tobacco was introduced in China by the Dutch traders between 1624 and 1660. Madak was prepared by blending opium from Java with domestic Chinese hemp and herbs, boiling the mix in pans and, finally, mixing with tobacco. It was smoked in bamboo pipes with coir fibre filter. The new addiction was limited to coastal territories around Taiwan Strait; further spread was hampered by the civil war that accompanied the fall of the Ming Dynasty. The new Qing Dynasty government was not aware of madak until 1683. The lucrative opium business continued spreading along the coast of Southern China, although exact chronology of this spread remains unknown. By 1720 the government saw madak smoking as a social evil that has corrupted not just the lowest classes, but the "good families" too. Smoking dens, where people congregated at night, were deemed as dangerous as heretical cults and political conspiracies. In 1729 the Yongzheng Emperor banned recreational smoking of madak. Medicinal use remained permitted.
=== Design of scientific investigations === Aarons has defined pharmacokinetics (PK) as the study of the complex chain of events that links a dose of drugs administered to a patient and the expected effect or response. PK is based on analysing the concentration of drugs and tracking how they are absorbed, distributed, metabolised and excreted within the patient. Some of his work has involved using optimal design theory to explore what makes a successful scientific investigation for pharmacokinetic studies and has said that this "involves the selection and a careful balance of a number of design factors, including the number and location of measurement times and the number of subjects to include in the study." According to Aarons, population pharmacokinetics studies which focus on what happens to the substances administered to a patient would need specific design factors that apply "statistical experimental design principles to non-linear population pharmacokinetic models." A later paper co-authored by Aarons, reviews the different approaches to optimal design of population pharmacokinetic and pharmacodynamic experiments and notes that some of the options may raise concerns at to their practicality. The paper did, however, conclude "that as the awareness about the benefits of this approach increases, more people will embrace it and ultimately will lead to more efficient population pharmacokinetic and pharmacodynamic experiments."
Sources: en.wikipedia.org
=== Structural details === The X−H distance is typically ≈110 pm, whereas the H···Y distance is ≈160 to 200 pm. The typical length of a hydrogen bond in water is 197 pm. The ideal bond angle depends on the nature of the hydrogen bond donor. The following hydrogen bond angles between a hydrofluoric acid donor and various acceptors have been determined experimentally:
==== TRIDENT-1 ==== Efficacy was evaluated in TRIDENT-1 (NCT03093116), a multicenter, single-arm, open-label, multi-cohort trial in 88 adult participants with locally advanced or metastatic neurotrophic tyrosine receptor kinase gene fusion-positive solid tumors who had either received a prior TRK tyrosine kinase inhibitor (TKI) (n=48) or were TKI-naïve (n=40). All participants were assessed for central nervous (CNS) lesions at baseline, and patients with symptomatic brain metastases were excluded. Tumor assessments were performed every eight weeks.
While at the Ohio State, he continued to explore additional applications, including the development of multitarget sRNAs that can be used for metabolic engineering, and the modification of human butyrylcholinesterase for the degradation of the chemical warfare nerve agents in collaboration with the Battelle Memorial Institute. Wood has joint appointments with Department of Chemistry and Biochemistry and the Molecular Biophysics Training Program at the Ohio State University. He is one of a small group of researchers worldwide focusing on intein implementation in various applications, along with Belfort and Tom Muir. Wood's research focuses on developing new technologies by recombining protein domains, particularly in biopharmaceutical development and manufacturing. He has continued refining these methods for biopharmaceutical development and manufacturing, and his work has drawn funding from the DARPA BioMOD project, NIH, NSF and US Army Research Office, projects as well as several industry sponsors. Wood was also involved in the development of protein switches for biotechnology funded by the NSF Career Award. Wood is an author of over 60 publications, six issued patents, two additional patent applications pending and an additional dozen book chapters or edited volumes. His publications have been cited nearly 4000 times. Wood is a member of the American Chemical Society, BIOT division, American Institute of Chemical Engineers, and International Society of Pharmaceutical Engineers.
Sources: en.wikipedia.org
Humans have known about the heart since ancient times, although its precise function and anatomy were not clearly understood. From the primarily religious views of earlier societies towards the heart, ancient Greeks are considered to have been the primary seat of scientific understanding of the heart in the ancient world. Aristotle considered the heart to be the organ responsible for creating blood; Plato considered the heart as the source of circulating blood and Hippocrates noted blood circulating cyclically from the body through the heart to the lungs. Erasistratos (304–250 BCE) noted the heart as a pump, causing dilation of blood vessels, and noted that arteries and veins both radiate from the heart, becoming progressively smaller with distance, although he believed they were filled with air and not blood. He also discovered the heart valves. The Greek physician Galen (2nd century CE) knew blood vessels carried blood and identified venous (dark red) and arterial (brighter and thinner) blood, each with distinct and separate functions. Galen, noting the heart as the hottest organ in the body, concluded that it provided heat to the body. The heart did not pump blood around, the heart's motion sucked blood in during diastole and the blood moved by the pulsation of the arteries themselves. Galen believed the arterial blood was created by venous blood passing from the left ventricle to the right through 'pores' between the ventricles. Air from the lungs passed from the lungs via the pulmonary artery to the left side of the heart and created arterial blood.
=== Size of displaced sediment === Critical stream power can be used to determine the stream competency of a river, which is a measure to determine the largest grain size that will be moved by a river. In rivers with large sediment sizes the relationship between critical unit stream power and sediment diameter displaced can be reduced to:
=== Consumption === Saffron's aroma is often described by connoisseurs as reminiscent of metallic honey with grassy or hay-like notes, while its taste has also been noted as hay-like and sweet. Consumed in large servings—more than a few threads per person per dish—saffron is experienced as bitter. Saffron also contributes a luminous yellow-orange colouring to foods. Saffron is widely used in Persian, Indian, European, and Arab cuisines. Confectioneries and liquors also often include saffron. Saffron is used in dishes ranging from the jewelled rice and khoresh of Iran, the Milanese risotto of Italy, the paella of Spain, the bouillabaisse of France, to the biryani with various meat accompaniments in South Asia. Saffron is also used in the preparation of the Golden Ham, a precious dry-cured ham made with saffron from San Gimignano in Tuscany. Common saffron substitutes include safflower (Carthamus tinctorius, which is often sold as "Portuguese saffron" or "açafrão"), annatto, and turmeric (Curcuma longa). In Medieval Europe, turmeric was also known as "Indian saffron" because of its yellow-orange colour.
In 1998, Firehouse Subs surpassed 10 locations, and later that year opened the first location outside of Florida. In 2000, the founders decided to take a different approach, using consultants to plan franchise growth. They were able to set up financing for potential franchisees. The second wave of franchising began in 2001. In 2011, Firehouse Subs opened its first franchises in the U.S. territory of Puerto Rico, via local franchisee Caribbean Restaurants. By 2012 the company reached 500 locations, ending the year with nearly 600. In July 2016, Firehouse Subs opened its 1,000th location. In 2015, Firehouse Subs opened its first locations in Canada, with its first location opening in Oshawa, Ontario in October with franchisee OnFire Restaurant Group. Currently, the group operates 50 Canadian restaurants, with plans to open a total of 90 in Ontario alone. The chain also launched a loyalty program. In June 2017, Firehouse Subs opened its first airport location at Jacksonville International. In December 2017, the brand's second airport location opened at Orlando International. In April 2018, the chain opened its first on-campus location at Western New England University. In 2020 the chain opened a location at Jacksonville's Baptist Medical Center. On November 15, 2021, Burger King parent Restaurant Brands International announced that it would acquire Firehouse Subs for $1 billion. The acquisition was completed on December 15, 2021. On June 22, 2023, Firehouse Subs opened its first location outside North America in Zurich, Switzerland.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.